title: [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
abstract: We conducted a multicenter early phase II study to evaluate the feasibility and therapeutic efficacy of high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (auto-PBSCT) for the treatment of intermediate grade non-Hodgkin's lymphoma (IG-NHL). High-dose etoposide or cyclophosphamide followed by G-CSF was used for PBSC mobilization, and a sufficient number of CD34+ cells (> 1 x 10(6)/kg) were collected. Out of 81 enrolled patients, 50 received high-dose chemotherapy with auto-PBSCT; Hematologic recovery after transplantation was rapid. The incidence of grade III/IV toxicity (Bearman) was about 6%; treatment-related mortality was 6% (3/50). The Disease-free survival rate for the patients in complete remission who received high-dose chemotherapy with auto-PBSCT was better than that for the patients who were treated with conventional chemotherapy (57% vs 35%). These preliminary results indicated that high-dose chemotherapy with auto-PBSCT is feasible and effective. A prospective randomized phase III clinical trial will be required to assess the efficacy of high-dose chemotherapy with auto-PBSCT as a post-remission therapy for IG-NHL.
authors.forename: T
authors.initials: T
authors.lastname: Chou
authors.forename: T
authors.initials: T
authors.lastname: Ishiguro
authors.forename: K
authors.initials: K
authors.lastname: Imajo
authors.forename: F
authors.initials: F
authors.lastname: Kawano
authors.forename: H
authors.initials: H
authors.lastname: Gondo
authors.forename: M
authors.initials: M
authors.lastname: Kasai
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Koike
authors.forename: C
authors.initials: C
authors.lastname: Shimazaki
authors.forename: M
authors.initials: M
authors.lastname: Hara
authors.forename: K
authors.initials: K
authors.lastname: Shinagawa
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: F
authors.initials: F
authors.lastname: Takaku
authors.forename: M
authors.initials: M
authors.lastname: Harada
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous; D016896:Treatment Outcome